BRPI1010550A2 - formas de dosagem, e, processo para a produção de preparações para formas de dosagem de substãncias ativas fracamente solúveis e, água. - Google Patents
formas de dosagem, e, processo para a produção de preparações para formas de dosagem de substãncias ativas fracamente solúveis e, água.Info
- Publication number
- BRPI1010550A2 BRPI1010550A2 BRPI1010550A BRPI1010550A BRPI1010550A2 BR PI1010550 A2 BRPI1010550 A2 BR PI1010550A2 BR PI1010550 A BRPI1010550 A BR PI1010550A BR PI1010550 A BRPI1010550 A BR PI1010550A BR PI1010550 A2 BRPI1010550 A2 BR PI1010550A2
- Authority
- BR
- Brazil
- Prior art keywords
- dosage forms
- water
- active substances
- poorly soluble
- soluble active
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title 2
- 239000013543 active substance Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F283/00—Macromolecular compounds obtained by polymerising monomers on to polymers provided for in subclass C08G
- C08F283/06—Macromolecular compounds obtained by polymerising monomers on to polymers provided for in subclass C08G on to polyethers, polyoxymethylenes or polyacetals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Graft Or Block Polymers (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09160129 | 2009-05-13 | ||
PCT/EP2010/056447 WO2010130728A2 (de) | 2009-05-13 | 2010-05-11 | Feste pharmazeutischen zubereitungen enthaltend copolymere auf basis von polyethern in kombination mit wasserschwerlöslichen polymeren |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI1010550A2 true BRPI1010550A2 (pt) | 2016-03-15 |
BRPI1010550A8 BRPI1010550A8 (pt) | 2019-09-03 |
BRPI1010550B1 BRPI1010550B1 (pt) | 2019-11-05 |
Family
ID=42262240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1010550-6A BRPI1010550B1 (pt) | 2009-05-13 | 2010-05-11 | formas de dosagem, e, processo para a produção de preparações para formas de dosagem de substâncias ativas fracamente solúveis em água |
Country Status (6)
Country | Link |
---|---|
US (2) | US9555002B2 (pt) |
EP (1) | EP2429492B1 (pt) |
JP (1) | JP5654002B2 (pt) |
CN (1) | CN102458368B (pt) |
BR (1) | BRPI1010550B1 (pt) |
WO (1) | WO2010130728A2 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI1010550B1 (pt) | 2009-05-13 | 2019-11-05 | Basf Se | formas de dosagem, e, processo para a produção de preparações para formas de dosagem de substâncias ativas fracamente solúveis em água |
JP5758899B2 (ja) | 2009-09-17 | 2015-08-05 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | 活性物質を含有するコーティングにより被覆されたペレット |
BR112012005938A2 (pt) * | 2009-09-18 | 2016-03-15 | Basf Se | formas de dosagem, e, processo para produzir preparações para formas de dosagem de ingredientes ativos de baixa solubilidade em água |
JP2013505222A (ja) | 2009-09-18 | 2013-02-14 | ビーエーエスエフ ソシエタス・ヨーロピア | 親水性ポリマーと組み合わせたポリエーテルに基づく両親媒性コポリマーを含有する速溶性固体医薬製剤 |
US8636929B2 (en) | 2010-05-21 | 2014-01-28 | Basf Se | Nanoporous foamed active compound-containing preparations based on pharmaceutically acceptable thermoplastically workable polymers |
US8715729B2 (en) | 2010-12-22 | 2014-05-06 | Basf Se | Rapidly disintegrating, solid coated dosage form |
EP2654731B1 (en) * | 2010-12-23 | 2016-07-27 | AbbVie Deutschland GmbH & Co. KG | Solid retard formulations based on solid dispersions |
CN103764125A (zh) * | 2011-08-30 | 2014-04-30 | 根特大学 | 多层释放制剂 |
EP2572731A1 (en) * | 2011-09-26 | 2013-03-27 | Abbott GmbH & Co. KG | Formulations based on solid dispersions |
US20160193151A1 (en) * | 2015-01-06 | 2016-07-07 | Maria Del Pilar Noriega Escobar | Dosage form incorporating an amorphous drug solid solution |
GB201502073D0 (en) * | 2015-02-09 | 2015-03-25 | Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd | HDEG technology |
CA3073195A1 (en) | 2017-08-15 | 2019-02-21 | Nephron Pharmaceuticals Corporation | Aqueous nebulization composition |
WO2019063478A1 (en) * | 2017-09-26 | 2019-04-04 | Capsugel Belgium Nv | SUB-MICRONIC PARTICLE FORMULATIONS |
CN108623744B (zh) * | 2018-06-01 | 2020-12-15 | 辽宁奥克医药辅料股份有限公司 | 共聚物、增溶剂及制备方法 |
CN111840231B (zh) * | 2020-06-24 | 2022-10-11 | 浙江工业大学 | 一种吡罗昔康纳米晶的制备方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19719187A1 (de) | 1997-05-07 | 1998-11-12 | Basf Ag | Verwendung von Copolymerisaten des N-Vinyl-pyrrolidons in Zubereitungen wasserunlöslicher Stoffe |
DE19811919A1 (de) | 1998-03-18 | 1999-09-23 | Basf Ag | Verwendung von Copolymerisaten monoethylenisch ungesättigter Carbonsäuren als Solubilisatoren |
DE19814739A1 (de) | 1998-04-02 | 1999-10-07 | Basf Ag | Verwendung von Polyalkylenoxid-haltigen Pfropfpolymerisaten als Solubilisatoren |
DK1067910T3 (da) * | 1998-04-03 | 2004-10-04 | Egalet As | Komposition med styret afgivelse |
DE19935063A1 (de) | 1999-07-28 | 2001-02-01 | Basf Ag | Pfropfpolymerisate als Gashydratinhibitoren |
MXPA06007512A (es) | 2003-12-31 | 2006-08-31 | Pfizer Prod Inc | Composiciones solidas farmaceuticas estabilizadas de farmacos de baja solubilidad, poloxameros y polimeros estabilizadores. |
DE102005026755A1 (de) * | 2005-06-09 | 2006-12-14 | Basf Ag | Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung |
DE102005053066A1 (de) | 2005-11-04 | 2007-05-10 | Basf Ag | Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen |
CA2597740C (en) * | 2006-04-26 | 2012-10-16 | Supernus Pharmaceuticals, Inc. | Modified-release preparations containing oxcarbazepine and derivatives thereof |
CA2673111A1 (en) * | 2006-12-07 | 2008-06-19 | Schering Corporation | Ph sensitive matrix formulation |
WO2009013202A1 (de) * | 2007-07-26 | 2009-01-29 | Basf Se | Verfahren zur herstellung von durch pfropfpolymerisation in lösung erhaltenen copolymeren auf basis von polyethern in fester form |
AU2008334580A1 (en) | 2007-12-12 | 2009-06-18 | Basf Se | Salts of active ingredients with polymeric counter-ions |
CN102164583B (zh) | 2008-09-25 | 2013-11-06 | 巴斯夫欧洲公司 | 聚醚基和乙烯基单体基共聚物作为包含固体活性成分的剂型用粘合剂的用途 |
EP2349218B1 (de) | 2008-10-07 | 2013-09-18 | Basf Se | Verfahren zur herstellung oraler darreichungsformen mit kontrollierter freisetzung |
EP2382035A1 (de) | 2008-12-23 | 2011-11-02 | Basf Se | Verwendung von copolymeren auf basis von polyethern und vinylmonomeren als stabilisierungsmittel für emulsionen |
US8790703B2 (en) | 2009-03-31 | 2014-07-29 | Basf Se | Method for producing preparations of substances poorly soluble in water |
BRPI1010550B1 (pt) | 2009-05-13 | 2019-11-05 | Basf Se | formas de dosagem, e, processo para a produção de preparações para formas de dosagem de substâncias ativas fracamente solúveis em água |
-
2010
- 2010-05-11 BR BRPI1010550-6A patent/BRPI1010550B1/pt active IP Right Grant
- 2010-05-11 EP EP10718209.9A patent/EP2429492B1/de active Active
- 2010-05-11 JP JP2012510270A patent/JP5654002B2/ja active Active
- 2010-05-11 CN CN201080026115.8A patent/CN102458368B/zh active Active
- 2010-05-11 US US13/319,575 patent/US9555002B2/en active Active
- 2010-05-11 WO PCT/EP2010/056447 patent/WO2010130728A2/de active Application Filing
-
2016
- 2016-11-29 US US15/362,957 patent/US10328150B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
BRPI1010550B1 (pt) | 2019-11-05 |
EP2429492B1 (de) | 2014-06-25 |
EP2429492A2 (de) | 2012-03-21 |
JP5654002B2 (ja) | 2015-01-14 |
US9555002B2 (en) | 2017-01-31 |
JP2012526765A (ja) | 2012-11-01 |
US20170072059A1 (en) | 2017-03-16 |
WO2010130728A2 (de) | 2010-11-18 |
US20120053248A1 (en) | 2012-03-01 |
BRPI1010550A8 (pt) | 2019-09-03 |
WO2010130728A3 (de) | 2011-04-07 |
CN102458368B (zh) | 2014-02-26 |
CN102458368A (zh) | 2012-05-16 |
US10328150B2 (en) | 2019-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1010550A2 (pt) | formas de dosagem, e, processo para a produção de preparações para formas de dosagem de substãncias ativas fracamente solúveis e, água. | |
BRPI1016215A2 (pt) | processo para á preparação de um comprimido de desintegração rápida, sistema para realizar um processo, e, embalagem. | |
BRPI1006162A2 (pt) | "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto". | |
BR112013009486A2 (pt) | processo para preparação de formas de dosagem gastrirretentivas multiparticuladas | |
BRPI0924622A2 (pt) | composições para tratamento de tecidos, processo de fabricação, e método de uso. | |
BRPI0822756A2 (pt) | sistema de prótese de válvula cardíaca e processo para produzir prótese de válvula cardíaca. | |
BR112012020596A2 (pt) | substrato para a imobilização de substâncias funcionais e processo para preparar o mesmo. | |
BR112012003804A2 (pt) | Curativo para ferimentos, uso do mesmo, e, método para formar um curativo para ferimentos. | |
BR112013030521A2 (pt) | preparação líquida para proteção biológica de plantas, método para a produção da mesma e respectiva utilização. | |
BR112012000882A2 (pt) | Preparação cosmética capilar e método para aplicação. | |
BRPI0907909A2 (pt) | Sistema, e, processo para a produção e uso do mesmo | |
BRPI0919018A2 (pt) | sal farmaceuticamente aceitável, uso de sal, e, processo para a preparação de sal | |
EA201001402A1 (ru) | Фармацевтические растворы, способ получения и терапевтическое применение | |
BR112013023471A2 (pt) | cocristal de n-[2-(7-metóxi-1-naftil) etil]acetamina, e, processo para preparar um cocristal. | |
BRPI1014547A2 (pt) | composto, e, processo para preparar um composto. | |
BRPI1012651A2 (pt) | processo para produzir preparações de substâncias fracamente solúveis em água | |
BRPI1013396A2 (pt) | composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto. | |
BR112012001030A2 (pt) | método para tratar a degeneração macular, e, uso de um composto. | |
BR112012000423A2 (pt) | catalizador enzimático heterogêneo, processo de preparação, e, utilização do mesmo. | |
BRPI0813438A2 (pt) | Processo para preparar um composto, uso de um composto, e, composto. | |
BRPI1011992A2 (pt) | solução catalítica, e, processo para preparar aldeídos | |
IT1400714B1 (it) | Processo ed intermedi per la preparazione di un principio attivo. | |
BRPI1009345A2 (pt) | sistema de administracao de droga, uso de um sistema de administracao de droga, e, metodo pata tratar doencas | |
BRPI0820289A2 (pt) | Processo para preparar ácido cianídrico, e, uso de um microevaporador. | |
BRPI0919694A2 (pt) | composto, composto farmacêutica, uso de um composto, e, método de tratamento de uma doença. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/05/2010, OBSERVADAS AS CONDICOES LEGAIS. |